Iambic Therapeutics, Inc.: AI Platform Monetization Expands Across San Diego Facilities as S-1 Filing Signals Cash Runway Extension to 61.5 Months
Date : 2026-09-29
Reading : 159
HDIN Executive Takeaways
1. Iambic Therapeutics, Inc. [NASDAQ: IAM] bolstered standalone liquidity ($207.88 million at June 30, 2026) via $66.50 million in post-period convertible notes, expanding pro forma runway to 61.5 months at a monthly burn of $4.46 million.
2. Dual-track monetization delivered $74.70 million in cumulative partner cash through September 18, 2026, while contracted deferred revenue reached $53.56 million across multinational partners including Takeda Pharmaceuticals U.S.A., Inc. and AbbVie Group Holdings Limited.
3. Pre-IPO investors holding $394.04 million in temporary equity convert 1-for-1 into common shares, shifting historical book deficit of $(9.85) per share into a pro forma positive tangible book value of $0.93 per share.
Segmental Realities, Revenue Recognition, and Balance Sheet Transformation
Iambic Therapeutics, Inc. manages operations as a single reportable operating segment headquartered in the United States of America. Commercial product revenue stands at zero. All historical inflows derive from collaborative research services, platform enablement fees, and milestone achievements governed under FASB ASC Topic 606.
Top-line collaboration revenue scaled from $1.19 million in FY 2024 to $9.43 million in FY 2025 (+689.4% year-over-year) and reached $12.75 million in 1H 2026, reflecting a 224.7% expansion against the $3.93 million recorded in 1H 2025. Cumulative gross capital collected across all sources from inception through September 18, 2026, totaled $536.50 million, consisting of $461.80 million in private equity/debt proceeds and $74.70 million in non-dilutive partner cash.
The company disaggregates collaboration inflows into upfront/research service fees and success-based milestones. In 1H 2026, upfront and research service fees represented approximately $12.15 million, while the company recognized its first success-based research milestone of approximately $0.60 million under its agreement with Revolution Medicines, Inc. [NASDAQ: RVMD]. Commercial sales-based royalties remain at zero.
Table Financial Performance, Operating Expenses, and Cash Flow Profile (FY2024–1H FY2026)
*Note 1: AbbVie executed post-period on September 18, 2026; $40.00 million nonrefundable upfront received in Q3 2026.
*Note 2: Bayer executed on June 20, 2026; zero revenue recognized in 1H 2026 with $4.00 million remaining transaction price.
*Note 3: Represents total Cash, Cash Equivalents, and Restricted Cash at June 30, 2025.
*Note 4: Excludes $560 thousand in restricted cash deposited under a letter of credit for facility leases; total cash, equivalents, and restricted cash reached $208.44 million at June 30, 2026.
Research and development represented 84.5% of total operating expenses in FY 2025 ($77.53 million of $91.78 million) and 86.2% in 1H 2026 ($57.15 million of $66.26 million). Direct clinical costs allocated to lead asset IAM1363 expanded 111.3% year-over-year in 1H 2026 to $17.40 million (up from $8.24 million in 1H 2025), driven by clinical site activations in the Phase 1/1b basket trial (IAM1363-01) and Chemistry, Manufacturing, and Controls (CMC) batch synthesis.
Cloud compute and data storage expenditure expanded 154.1% year-over-year in 1H 2026 to $4.36 million (compared to $1.71 million in 1H 2025 and $6.01 million in FY 2025, up 175.7% from $2.18 million in FY 2024), reflecting compute commitments to train the 41-billion-parameter Enchant v3 mixture-of-experts model on cluster architecture provided by Lambda, Inc. and NVIDIA Corporation [NASDAQ: NVDA]. Stock-based compensation across R&D expanded from $1.03 million in FY 2024 (6.3% of R&D personnel cost) to $1.43 million in FY 2025 (5.7%), and from $0.69 million in 1H 2025 (6.2%) to $1.44 million in 1H 2026 (8.1%).
Operating cash outflows reached $24.85 million in 1H 2026, establishing a quarterly operating burn rate of $12.43 million ($4.14 million monthly). Including 1H 2026 capital expenditures of $1.94 million, total free cash outflow reached $26.79 million ($13.39 million quarterly; $4.46 million monthly).
Table Cash Burn Rate and Liquidity Runway Scenario Analysis (FY2025–1H FY2026)
Between August 14, 2026, and September 11, 2026, Iambic Therapeutics, Inc. issued $66.50 million in 8.0% subordinated convertible promissory notes maturing August 14, 2028. The notes automatically convert at initial public offering closing into common stock at a price equal to the lower of an 85% multiple of the public offering price (a 15% discount) or the per-share value implied by a $900.00 million valuation cap. Participating note purchasers include institutional investors KKR & Co. Inc., Insight Partners, Perceptive Advisors, Millennium Management LLC, Laurion Capital Management, Catalio Capital Management ($10.00 million), Ascenta Capital ($5.53 million), Abingworth ($2.10 million), and The Rastetter Family Trust ($0.11 million). Factoring in the $66.50 million note proceeds, effective pro forma cash reserves total $274.38 million.
Deferred revenue liability expanded from zero at year-end 2023 to $9.34 million in 2024 (current: $6.64 million; non-current: $2.70 million), $20.39 million in 2025 (current: $11.31 million; non-current: $9.08 million), and $53.56 million as of June 30, 2026 (current: $30.88 million; non-current: $22.68 million). Operating cash flows in 1H 2026 benefited from a $33.18 million net working capital expansion in deferred revenue driven by partner upfront fees.
As of June 30, 2026, the company held $53.40 million in contracted unearned transaction price allocated to remaining performance obligations:
* Takeda Pharmaceuticals U.S.A., Inc.: $28.00 million, amortized through 2028 via cost-to-cost input and straight-line platform enablement output methods. Initial terms secured $27.00 million upfront, cost reimbursements, and potential downstream milestones exceeding $1.70 billion across 3 initial targets (plus options for 3 additional targets), with tiered royalties from mid-single to low-teens percentages.
* Revolution Medicines, Inc.: $17.60 million, amortized through 2030 across active and enablement periods for customized NeuralPLexer and PropANE foundation models targeting molecular glues.
* Bayer Healthcare LLC: $4.00 million, amortized through 2028 using direct labor hours under a June 2026 discovery agreement for small-molecule oncology candidates.
* H. Lundbeck A/S: $3.80 million, amortized through 2027 under a 36-month collaboration signed September 23, 2024, providing $10.00 million upfront, $212.50 million in downstream milestone potential, and mid-single to low-teens royalties.
* AbbVie Group Holdings Limited: Executed September 18, 2026, securing a $40.00 million nonrefundable upfront payment, up to $670.00 million in aggregate milestones, and mid-single to low-teens royalties across two initial targets in oncology, neuroscience, and immunology.
Downstream un-risked milestone rights total more than $2.58 billion across active collaboration agreements, but remain 100% constrained under ASC Topic 606 variable consideration criteria.
Private equity capital accumulation reflects a 9.35x valuation step-up from founding Series Seed to the final pre-IPO Series B-4 equity financing round:
Table Preferred Equity Financing History and Institutional Capital Participation Overview (2020–2026)
*Note: Debt principal; carries 8.0% coupon and converts automatically upon initial public offering completion.
Preferred stock is recorded as temporary equity on the balance sheet at a carrying value of $394.04 million ($395.29 million liquidation preference) due to deemed liquidation redemption rights outside the entity's control. Senior liquidation preferences total $323.62 million across Series B, B-2, B-3, and B-4 shares, while Junior Preferred preferences total $71.67 million. All 150,004,272 preferred shares convert 1-for-1 into common shares upon closing of a qualified public offering raising at least $50.00 million gross at a minimum per-share price of $7.4280, or via a class vote.
Conversion of preferred shares resolves historical balance sheet insolvency:
As of June 30, 2026, historical assets totaled $237.20 million against liabilities of $75.72 million and temporary equity of $394.04 million, yielding a stockholders' deficit of $(232.56) million across 23,605,655 common shares, or $(9.85) per share. Reclassifying temporary equity into common equity generates a pro forma net tangible book value of $161.48 million across 173,609,927 common shares, establishing a positive pro forma book value of $0.93 per share prior to the receipt of initial public offering proceeds or convertible debt conversion. Existing stock options (17,208,599 contracts outstanding) carry a weighted-average exercise price of $1.31 per share.
Laboratory Infrastructure, AI Architecture, and Supply Chain Concentration
Iambic Therapeutics, Inc. isolates operations into an internal discovery architecture while outsourcing physical clinical production to contract partners. The company's automated wet-lab workflow runs microscale chemistry and biology to feed machine-learning models, eliminating capital allocation toward commercial-scale manufacturing plants.
Pre-training and inference for Enchant v3 (scaled from 1 billion parameters in v1 to 7 billion in v2 and 41 billion in v3) and NeuralPLexer flow-matching architectures operate through third-party cloud infrastructure managed by Amazon Web Services and Lambda, Inc., supported by a technology alignment with NVIDIA Corporation. Cloud compute agreements contain no non-cancelable purchase commitments and are terminable upon 14 to 120 days' written notice.
Physical laboratory and administrative operations span domestic facilities and international operating subsidiaries:
* Headquarters & Primary Automation Lab: 5627 Oberlin Drive, Suite 120, San Diego, California, United States of America. Occupies 12,545 square feet of laboratory and administrative space under a lease running through June 2031.
* Cray Court Expansion Headquarters: Cray Court, San Diego, California, United States of America. Executed an operating lease in January 2026 (amended March and July 2026) for 95,985 square feet of specialized laboratory and headquarters space. Phased occupancy initiates in late 2026 to scale automated wet-lab throughput, representing $25.00 million in aggregate base rent commitments over a 90-month lease term.
* International Subsidiaries: Operates Iambic Therapeutics UK Ltd from an office facility in Bristol, United Kingdom, and holds corporate entity Iambic Therapeutics IRE Ltd in Dublin, Republic of Ireland, alongside secondary leased facilities in Massachusetts and Virginia, United States of America.
Clinical and commercial manufacturing remains 100% externalized. The company owns zero commercial Good Manufacturing Practice (GMP) production facilities. Production of active pharmaceutical ingredient (API) drug substance for lead asset IAM1363 depends on a single contract manufacturer, while clinical drug product supply is distributed across a limited CDMO panel. Significant research support and precursor chemistry vendor operations are concentrated in the People's Republic of China, including active service agreements with WuXi AppTec Co., Ltd. Operations maintain exposure to potential trade restrictions under the United States BIOSECURE Act (NDAA 2026 Section 851) and prospective import tariff modifications.
The wholly owned therapeutic pipeline features three core oncology programs generated entirely via internal platform operations, carrying zero university royalty burdens, upfront maintenance charges, or partner reversion options:
In the ongoing IAM1363-01 Phase 1/1b clinical trial, the Recommended Part 3 Dose (RP3D) was established at 960 mg orally once daily (QD). In efficacy-evaluable patients treated at or above 960 mg QD (N=53), monotherapy produced a systemic best overall response (BoR) partial response rate of 36% (19 of 53 patients) and a confirmed objective response rate (ORR) of 23% (12 of 53 patients, with 4 partial responses pending confirmation).
Among patients presenting with measurable intracranial brain metastases under RANO-BM assessment criteria (N=22), intracranial BoR partial response reached 41% (9 of 22 patients), with a confirmed intracranial ORR of 18% (4 of 22 patients). Notably, 8 of the 9 intracranial partial responses occurred in individuals whose disease had previously progressed through both fam-trastuzumab deruxtecan-nxki (T-DXd) and tucatinib.
Safety metrics at the 960 mg QD dose level (N=68 evaluable subjects) demonstrate a 6% Grade 3 treatment-related adverse event (TRAE) incidence (4 of 68 patients), with zero reported Grade 4 or Grade 5 adverse events.
Table Treatment-Related Adverse Event Profile by Severity Grade (Clinical Trial Safety Analysis)
*Note: Single Grade 3 pneumonitis case resolved following permanent discontinuation of investigational drug product.
Intellectual property filings anchor protection around composition of matter:
* IAM1363: 1 issued U.S. patent (statutory expiration 2043, excluding patent term adjustments or extensions), 1 issued foreign patent, 6 U.S. provisionals, 5 PCT applications, 5 U.S. non-provisionals, and 32 foreign national filings providing secondary formulation coverage to 2046+.
* IAM217: 2 U.S. provisional applications, 3 PCT filings, 3 pending U.S. non-provisionals, and 14 foreign filings with projected expirations across 2044–2045.
* IAM-C1: 2 U.S. provisionals, 1 PCT application, and 1 foreign application projecting composition-of-matter expiration to 2046.
* Platform Engine IP: NeuralPLexer Family 1 co-owned with the California Institute of Technology and NVIDIA Corporation (projected expiration 2044) alongside solely owned Family 2 (projected expiration 2045). Enchant transformer architecture encompasses Caltech co-owned families (expiring 2041) and solely owned filings (expiring 2045).
HDIN Institutional Verdict
Form S-1 documentation validates Iambic Therapeutics, Inc.'s structural claim of compressed discovery cycles, delivering IAM1363 from program initiation to Phase 1 in 2.0 years (against the 5.5-year industry benchmark) and establishing brain penetrance for IAM217 within 6 months. Platform validation is confirmed commercially through non-dilutive partner commitments totaling $74.70 million collected and $53.40 million in locked unearned revenue amortizing through 2030.
However, institutional risk centers on three structural operational vulnerabilities:
While statutory non-compete limits under California and United Kingdom labor codes leave proprietary model know-how vulnerable to employee mobility, Iambic's clean capitalization structure (single-class post-IPO voting, no founder super-shares, and zero academic royalty tails) and $274.38 million pro forma cash reserve provide a defensible operational runway through planned 2027 registrational trials.
Presentation Download & Video Access:
- Presentation Download: Click the PDF download link under 'Related Topics' to access the full institutional presentation of this report.
- Video Link: Click this link to watch the HDIN analyst briefing on YouTube.
About HDIN Research:
HDIN Research is a premier global market intelligence and strategic advisory firm specializing in institutional-grade financial analysis, supply chain audits, and macroeconomic forecasting. Our dedicated sector analysts deliver actionable, data-driven insights tailored for private equity, hedge funds, and corporate strategy teams. Visit us at http://www.hdinresearch.com.
2026 AI Transparency Footer:
"This intelligence report was authored by HDIN Research analysts following a rigorous audit of official corporate filings. AI was utilized for massive-scale data synthesis and structural drafting, ensuring 100% inclusion of reported data points. All strategic insights, financial modeling, and final verdicts were verified by our editorial board to ensure professional accuracy and compliance with 2026 Google Search E-E-A-T standards."
1. Iambic Therapeutics, Inc. [NASDAQ: IAM] bolstered standalone liquidity ($207.88 million at June 30, 2026) via $66.50 million in post-period convertible notes, expanding pro forma runway to 61.5 months at a monthly burn of $4.46 million.
2. Dual-track monetization delivered $74.70 million in cumulative partner cash through September 18, 2026, while contracted deferred revenue reached $53.56 million across multinational partners including Takeda Pharmaceuticals U.S.A., Inc. and AbbVie Group Holdings Limited.
3. Pre-IPO investors holding $394.04 million in temporary equity convert 1-for-1 into common shares, shifting historical book deficit of $(9.85) per share into a pro forma positive tangible book value of $0.93 per share.
Segmental Realities, Revenue Recognition, and Balance Sheet Transformation
Iambic Therapeutics, Inc. manages operations as a single reportable operating segment headquartered in the United States of America. Commercial product revenue stands at zero. All historical inflows derive from collaborative research services, platform enablement fees, and milestone achievements governed under FASB ASC Topic 606.
Top-line collaboration revenue scaled from $1.19 million in FY 2024 to $9.43 million in FY 2025 (+689.4% year-over-year) and reached $12.75 million in 1H 2026, reflecting a 224.7% expansion against the $3.93 million recorded in 1H 2025. Cumulative gross capital collected across all sources from inception through September 18, 2026, totaled $536.50 million, consisting of $461.80 million in private equity/debt proceeds and $74.70 million in non-dilutive partner cash.
The company disaggregates collaboration inflows into upfront/research service fees and success-based milestones. In 1H 2026, upfront and research service fees represented approximately $12.15 million, while the company recognized its first success-based research milestone of approximately $0.60 million under its agreement with Revolution Medicines, Inc. [NASDAQ: RVMD]. Commercial sales-based royalties remain at zero.
Table Financial Performance, Operating Expenses, and Cash Flow Profile (FY2024–1H FY2026)
| Financial Performance Metric (USD in thousands, except per share data) | FY 2024 Audited (Ended Dec 31, 2024) | FY 2025 Audited (Ended Dec 31, 2025) | 1H 2025 Unaudited (6M Ended Jun 30, 2025) | 1H 2026 Unaudited (6M Ended Jun 30, 2026) | Accounting Recognition & SEC S-1 Reference |
| Collaboration Revenue | $1,194 | $9,426 | $3,928 | $12,753 | Input / Output Methods (pp. 11, 105, 108) |
| -- Takeda Pharmaceuticals U.S.A., Inc. | $0 | $0 | $0 | $6,153 | Cost-to-Cost / Straight-Line (p. 102) |
| -- H. Lundbeck A/S | $1,194 | $6,726 | $3,928 | $4,200 | Cost-to-Cost Input Method (p. 103) |
| -- Revolution Medicines, Inc. | $0 | $2,700 | $0 | $2,400 | Cost-to-Cost & Time-Elapsed (p. 102) |
| -- AbbVie Group Holdings Limited | $0 | $0 | $0 | $0* | Cost-to-Cost (Signed Sept 18, 2026) |
| -- Bayer Healthcare LLC | $0 | $0 | $0 | $0** | Direct Labor Hours (Signed June 2026) |
| Research & Development (R&D) Expense | $45,696 | $77,528 | $32,934 | $57,149 | Operating Line Item (pp. 11, 106, 108) |
| General & Administrative (G&A) Expense | $9,375 | $14,248 | $6,669 | $9,115 | Operating Line Item (pp. 11, 107, 109) |
| Total Operating Expenses | $55,071 | $91,776 | $39,603 | $66,264 | S-1 Summary Financial Data (p. 11) |
| Loss from Operations | $(53,877) | $(82,350) | $(35,675) | $(53,511) | S-1 Summary Financial Data (p. 11) |
| Net Loss | $(47,877) | $(77,295) | $(33,165) | $(50,116) | S-1 Summary Financial Data (p. 11) |
| Net Cash Used in Operating Activities | $(33,560) | $(58,823) | $(17,949) | $(24,852) | Statements of Cash Flows (pp. 111–112) |
| Capital Expenditures (Property & Equipment) | $(707) | $(1,280) | $(775) | $(1,937) | Statements of Cash Flows (pp. 111–112) |
| Ending Cash and Cash Equivalents | $141,579 | $180,539 | $122,866*** | $207,878**** | Consolidated Balance Sheets (pp. 12, 94) |
| Short-Term Marketable Securities | $0 | $0 | $0 | $0 | Level 1 Money Market Holdings (p. F-14) |
| Accumulated Deficit | $(117,872) | $(195,167) | $(151,037) | $(245,283) | Stockholders' Deficit Notes (p. F-30) |
*Note 2: Bayer executed on June 20, 2026; zero revenue recognized in 1H 2026 with $4.00 million remaining transaction price.
*Note 3: Represents total Cash, Cash Equivalents, and Restricted Cash at June 30, 2025.
*Note 4: Excludes $560 thousand in restricted cash deposited under a letter of credit for facility leases; total cash, equivalents, and restricted cash reached $208.44 million at June 30, 2026.
Research and development represented 84.5% of total operating expenses in FY 2025 ($77.53 million of $91.78 million) and 86.2% in 1H 2026 ($57.15 million of $66.26 million). Direct clinical costs allocated to lead asset IAM1363 expanded 111.3% year-over-year in 1H 2026 to $17.40 million (up from $8.24 million in 1H 2025), driven by clinical site activations in the Phase 1/1b basket trial (IAM1363-01) and Chemistry, Manufacturing, and Controls (CMC) batch synthesis.
Cloud compute and data storage expenditure expanded 154.1% year-over-year in 1H 2026 to $4.36 million (compared to $1.71 million in 1H 2025 and $6.01 million in FY 2025, up 175.7% from $2.18 million in FY 2024), reflecting compute commitments to train the 41-billion-parameter Enchant v3 mixture-of-experts model on cluster architecture provided by Lambda, Inc. and NVIDIA Corporation [NASDAQ: NVDA]. Stock-based compensation across R&D expanded from $1.03 million in FY 2024 (6.3% of R&D personnel cost) to $1.43 million in FY 2025 (5.7%), and from $0.69 million in 1H 2025 (6.2%) to $1.44 million in 1H 2026 (8.1%).
Operating cash outflows reached $24.85 million in 1H 2026, establishing a quarterly operating burn rate of $12.43 million ($4.14 million monthly). Including 1H 2026 capital expenditures of $1.94 million, total free cash outflow reached $26.79 million ($13.39 million quarterly; $4.46 million monthly).
Table Cash Burn Rate and Liquidity Runway Scenario Analysis (FY2025–1H FY2026)
| Liquidity Burn & Cash Runway Modeling Scenario | Effective Period Net Outflow (USD $M) | Quarterly Run-Rate (USD $M/qtr) | Monthly Run-Rate (USD $M/mo) | Standalone Runway ($207.88M Cash) | Pro Forma Runway ($274.38M Cash + Notes) |
| Scenario 1: 1H 2026 Net Operating Cash Outflow | $24.85 | $12.43 | $4.14 | 50.19 Months (~4.18 Years) | 66.24 Months (~5.52 Years) |
| Scenario 2: 1H 2026 Total Cash Burn (Operating + CapEx) | $26.79 | $13.39 | $4.46 | 46.56 Months (~3.88 Years) | 61.45 Months (~5.12 Years) |
| Scenario 3: FY 2025 Net Operating Cash Outflow | $58.82 | $14.71 | $4.90 | 42.41 Months (~3.53 Years) | 55.97 Months (~4.66 Years) |
| Scenario 4: FY 2025 Total Cash Burn (Operating + CapEx) | $60.10 | $15.03 | $5.01 | 41.51 Months (~3.46 Years) | 54.78 Months (~4.56 Years) |
Between August 14, 2026, and September 11, 2026, Iambic Therapeutics, Inc. issued $66.50 million in 8.0% subordinated convertible promissory notes maturing August 14, 2028. The notes automatically convert at initial public offering closing into common stock at a price equal to the lower of an 85% multiple of the public offering price (a 15% discount) or the per-share value implied by a $900.00 million valuation cap. Participating note purchasers include institutional investors KKR & Co. Inc., Insight Partners, Perceptive Advisors, Millennium Management LLC, Laurion Capital Management, Catalio Capital Management ($10.00 million), Ascenta Capital ($5.53 million), Abingworth ($2.10 million), and The Rastetter Family Trust ($0.11 million). Factoring in the $66.50 million note proceeds, effective pro forma cash reserves total $274.38 million.
Deferred revenue liability expanded from zero at year-end 2023 to $9.34 million in 2024 (current: $6.64 million; non-current: $2.70 million), $20.39 million in 2025 (current: $11.31 million; non-current: $9.08 million), and $53.56 million as of June 30, 2026 (current: $30.88 million; non-current: $22.68 million). Operating cash flows in 1H 2026 benefited from a $33.18 million net working capital expansion in deferred revenue driven by partner upfront fees.
As of June 30, 2026, the company held $53.40 million in contracted unearned transaction price allocated to remaining performance obligations:
* Takeda Pharmaceuticals U.S.A., Inc.: $28.00 million, amortized through 2028 via cost-to-cost input and straight-line platform enablement output methods. Initial terms secured $27.00 million upfront, cost reimbursements, and potential downstream milestones exceeding $1.70 billion across 3 initial targets (plus options for 3 additional targets), with tiered royalties from mid-single to low-teens percentages.
* Revolution Medicines, Inc.: $17.60 million, amortized through 2030 across active and enablement periods for customized NeuralPLexer and PropANE foundation models targeting molecular glues.
* Bayer Healthcare LLC: $4.00 million, amortized through 2028 using direct labor hours under a June 2026 discovery agreement for small-molecule oncology candidates.
* H. Lundbeck A/S: $3.80 million, amortized through 2027 under a 36-month collaboration signed September 23, 2024, providing $10.00 million upfront, $212.50 million in downstream milestone potential, and mid-single to low-teens royalties.
* AbbVie Group Holdings Limited: Executed September 18, 2026, securing a $40.00 million nonrefundable upfront payment, up to $670.00 million in aggregate milestones, and mid-single to low-teens royalties across two initial targets in oncology, neuroscience, and immunology.
Downstream un-risked milestone rights total more than $2.58 billion across active collaboration agreements, but remain 100% constrained under ASC Topic 606 variable consideration criteria.
Private equity capital accumulation reflects a 9.35x valuation step-up from founding Series Seed to the final pre-IPO Series B-4 equity financing round:
| Financing Series / Class | Issuance Timeframe | Share Price ($) | Shares Issued & Outstanding | Gross Inflow ($M) | Liquidation Preference ($M) | Major Participating Institutional Entities |
| Series Seed Preferred | Oct 2020 – 2021 | $0.34849 | 7,231,110 | $2.520 | $2.520 | Founding Investors & Seed Venture Capital Funds |
| Series A Preferred | 2021 – 2022 | $2.37310 | 28,295,040 | $66.951 | $67.147 | Institutional Syndicate Lead Investors |
| Series A-1 Preferred | 2022 | $1.89850 | 1,053,462 | $2.000 | $2.000 | Specialized Scientific Strategic Funds |
| Series B Preferred | Sept – Dec 2023 | $2.47600 | 42,904,185 | $106.231 | $106.231 | NVIDIA (
15.8M), Abingworth (
10.0M), Catalio (
1.0M) |
| Series B-2 Preferred | Apr – Oct 2024 | $2.97120 | 21,994,473 | $65.350 | $65.350 | Q Healthcare/QIA (
5.0M), Nexus (
3.0M), Rastetter ($1.0M) |
| Series B-3 Preferred | Nov 2025 – Jan 2026 | $3.10000 | 38,473,957 | $119.269 | $119.269 | QIA (
5.0M), Abingworth (
2.0M), CFO Dr. Secora ($1.0M) |
| Series B-4 Preferred | Apr – May 2026 | $3.26000 | 10,052,045 | $32.770 | $32.770 | Catalio Access Fund (
5.0M), Rastetter Trust ($0.26M) |
| 8.0% Convertible Notes | Aug – Sept 2026 | N/A (Debt) | N/A (Debt) | $66.500 | $66.500* | KKR, Insight, Perceptive, Millennium, Laurion, Catalio (
5.5M), Abingworth ($2.1M) |
| Total Preferred Portfolio | Inception – 2026 | ~$2.61 Wtd Avg | 150,004,272 | $461.591 | $395.287 | Unified Institutional Cap Table (Conversion 1:1 at IPO) |
Preferred stock is recorded as temporary equity on the balance sheet at a carrying value of $394.04 million ($395.29 million liquidation preference) due to deemed liquidation redemption rights outside the entity's control. Senior liquidation preferences total $323.62 million across Series B, B-2, B-3, and B-4 shares, while Junior Preferred preferences total $71.67 million. All 150,004,272 preferred shares convert 1-for-1 into common shares upon closing of a qualified public offering raising at least $50.00 million gross at a minimum per-share price of $7.4280, or via a class vote.
Conversion of preferred shares resolves historical balance sheet insolvency:
As of June 30, 2026, historical assets totaled $237.20 million against liabilities of $75.72 million and temporary equity of $394.04 million, yielding a stockholders' deficit of $(232.56) million across 23,605,655 common shares, or $(9.85) per share. Reclassifying temporary equity into common equity generates a pro forma net tangible book value of $161.48 million across 173,609,927 common shares, establishing a positive pro forma book value of $0.93 per share prior to the receipt of initial public offering proceeds or convertible debt conversion. Existing stock options (17,208,599 contracts outstanding) carry a weighted-average exercise price of $1.31 per share.
Laboratory Infrastructure, AI Architecture, and Supply Chain Concentration
Iambic Therapeutics, Inc. isolates operations into an internal discovery architecture while outsourcing physical clinical production to contract partners. The company's automated wet-lab workflow runs microscale chemistry and biology to feed machine-learning models, eliminating capital allocation toward commercial-scale manufacturing plants.
Pre-training and inference for Enchant v3 (scaled from 1 billion parameters in v1 to 7 billion in v2 and 41 billion in v3) and NeuralPLexer flow-matching architectures operate through third-party cloud infrastructure managed by Amazon Web Services and Lambda, Inc., supported by a technology alignment with NVIDIA Corporation. Cloud compute agreements contain no non-cancelable purchase commitments and are terminable upon 14 to 120 days' written notice.
Physical laboratory and administrative operations span domestic facilities and international operating subsidiaries:
* Headquarters & Primary Automation Lab: 5627 Oberlin Drive, Suite 120, San Diego, California, United States of America. Occupies 12,545 square feet of laboratory and administrative space under a lease running through June 2031.
* Cray Court Expansion Headquarters: Cray Court, San Diego, California, United States of America. Executed an operating lease in January 2026 (amended March and July 2026) for 95,985 square feet of specialized laboratory and headquarters space. Phased occupancy initiates in late 2026 to scale automated wet-lab throughput, representing $25.00 million in aggregate base rent commitments over a 90-month lease term.
* International Subsidiaries: Operates Iambic Therapeutics UK Ltd from an office facility in Bristol, United Kingdom, and holds corporate entity Iambic Therapeutics IRE Ltd in Dublin, Republic of Ireland, alongside secondary leased facilities in Massachusetts and Virginia, United States of America.
Clinical and commercial manufacturing remains 100% externalized. The company owns zero commercial Good Manufacturing Practice (GMP) production facilities. Production of active pharmaceutical ingredient (API) drug substance for lead asset IAM1363 depends on a single contract manufacturer, while clinical drug product supply is distributed across a limited CDMO panel. Significant research support and precursor chemistry vendor operations are concentrated in the People's Republic of China, including active service agreements with WuXi AppTec Co., Ltd. Operations maintain exposure to potential trade restrictions under the United States BIOSECURE Act (NDAA 2026 Section 851) and prospective import tariff modifications.
The wholly owned therapeutic pipeline features three core oncology programs generated entirely via internal platform operations, carrying zero university royalty burdens, upfront maintenance charges, or partner reversion options:
In the ongoing IAM1363-01 Phase 1/1b clinical trial, the Recommended Part 3 Dose (RP3D) was established at 960 mg orally once daily (QD). In efficacy-evaluable patients treated at or above 960 mg QD (N=53), monotherapy produced a systemic best overall response (BoR) partial response rate of 36% (19 of 53 patients) and a confirmed objective response rate (ORR) of 23% (12 of 53 patients, with 4 partial responses pending confirmation).
Among patients presenting with measurable intracranial brain metastases under RANO-BM assessment criteria (N=22), intracranial BoR partial response reached 41% (9 of 22 patients), with a confirmed intracranial ORR of 18% (4 of 22 patients). Notably, 8 of the 9 intracranial partial responses occurred in individuals whose disease had previously progressed through both fam-trastuzumab deruxtecan-nxki (T-DXd) and tucatinib.
Safety metrics at the 960 mg QD dose level (N=68 evaluable subjects) demonstrate a 6% Grade 3 treatment-related adverse event (TRAE) incidence (4 of 68 patients), with zero reported Grade 4 or Grade 5 adverse events.
Table Treatment-Related Adverse Event Profile by Severity Grade (Clinical Trial Safety Analysis)
| Treatment-Related Adverse Event Preferred Term | All Grades Incidence n (%) | Grade 1 Severity n (%) | Grade 2 Severity n (%) | Grade 3 Severity n (%) | Grade 4 / 5 Severity n (%) |
| Any Treatment-Related Adverse Event | 56 (82%) | -- | -- | 4 (6%) | 0 (0%) |
| Diarrhea | 36 (53%) | 31 (46%) | 4 (6%) | 1 (2%) | 0 (0%) |
| Nausea | 33 (49%) | 28 (41%) | 4 (6%) | 1 (2%) | 0 (0%) |
| Vomiting | 25 (37%) | 17 (25%) | 8 (12%) | 0 (0%) | 0 (0%) |
| Fatigue | 12 (18%) | 10 (15%) | 2 (3%) | 0 (0%) | 0 (0%) |
| Acute Kidney Injury / Blood Creatinine Increase | 1 (2%) | 0 (0%) | 0 (0%) | 1 (2%) | 0 (0%) |
| Pneumonitis | 1 (2%) | 0 (0%) | 0 (0%) | 1 (2%)* | 0 (0%) |
Intellectual property filings anchor protection around composition of matter:
* IAM1363: 1 issued U.S. patent (statutory expiration 2043, excluding patent term adjustments or extensions), 1 issued foreign patent, 6 U.S. provisionals, 5 PCT applications, 5 U.S. non-provisionals, and 32 foreign national filings providing secondary formulation coverage to 2046+.
* IAM217: 2 U.S. provisional applications, 3 PCT filings, 3 pending U.S. non-provisionals, and 14 foreign filings with projected expirations across 2044–2045.
* IAM-C1: 2 U.S. provisionals, 1 PCT application, and 1 foreign application projecting composition-of-matter expiration to 2046.
* Platform Engine IP: NeuralPLexer Family 1 co-owned with the California Institute of Technology and NVIDIA Corporation (projected expiration 2044) alongside solely owned Family 2 (projected expiration 2045). Enchant transformer architecture encompasses Caltech co-owned families (expiring 2041) and solely owned filings (expiring 2045).
HDIN Institutional Verdict
Form S-1 documentation validates Iambic Therapeutics, Inc.'s structural claim of compressed discovery cycles, delivering IAM1363 from program initiation to Phase 1 in 2.0 years (against the 5.5-year industry benchmark) and establishing brain penetrance for IAM217 within 6 months. Platform validation is confirmed commercially through non-dilutive partner commitments totaling $74.70 million collected and $53.40 million in locked unearned revenue amortizing through 2030.
However, institutional risk centers on three structural operational vulnerabilities:
While statutory non-compete limits under California and United Kingdom labor codes leave proprietary model know-how vulnerable to employee mobility, Iambic's clean capitalization structure (single-class post-IPO voting, no founder super-shares, and zero academic royalty tails) and $274.38 million pro forma cash reserve provide a defensible operational runway through planned 2027 registrational trials.
Presentation Download & Video Access:
- Presentation Download: Click the PDF download link under 'Related Topics' to access the full institutional presentation of this report.
- Video Link: Click this link to watch the HDIN analyst briefing on YouTube.
About HDIN Research:
HDIN Research is a premier global market intelligence and strategic advisory firm specializing in institutional-grade financial analysis, supply chain audits, and macroeconomic forecasting. Our dedicated sector analysts deliver actionable, data-driven insights tailored for private equity, hedge funds, and corporate strategy teams. Visit us at http://www.hdinresearch.com.
2026 AI Transparency Footer:
"This intelligence report was authored by HDIN Research analysts following a rigorous audit of official corporate filings. AI was utilized for massive-scale data synthesis and structural drafting, ensuring 100% inclusion of reported data points. All strategic insights, financial modeling, and final verdicts were verified by our editorial board to ensure professional accuracy and compliance with 2026 Google Search E-E-A-T standards."